-
Company Insights
New![]()
Innovation and Patenting activity of CM Hospitalar SA Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CM Hospitalar SA Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
New![]()
Innovation and Patenting activity of CMS Energy Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CMS Energy Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CM-101 in Primary Sclerosing Cholangitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Primary Sclerosing Cholangitis Drug Details: CM-101 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CM-101 in Systemic Sclerosis (Scleroderma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Systemic Sclerosis (Scleroderma) Drug Details: CM-101 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CMS-121 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CMS-121 in Alzheimer's Disease Drug Details:CMS-121 is under development for the treatment of Alzheimer's disease (AD)....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CM-24 in Metastatic Adenocarcinoma of The Pancreas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CM-24 in Metastatic Adenocarcinoma of The Pancreas Drug Details:CM-24 is under development for pancreatic cancer, melanoma, ovarian cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CM-AT in Autism Spectrum Disorder (ASD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CM-AT in Autism Spectrum Disorder (ASD) Drug Details: CM-AT (LUMINENZ-AT) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CM-24 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-24 in Pancreatic Ductal Adenocarcinoma Drug Details: CM-24 is under development for pancreatic cancer, melanoma, ovarian cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CM-101 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: CM-101 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CM-101 in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CM-101 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:CM-101 is under development for the treatment of systemic sclerosis, non-alcoholic...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.